HER2 Testing in Gastric and Gastroesophageal Junction Cancers

Whitney-Miller, Christa L.

doi:10.1097/pai.0b013e31822c3a0f

Cited by 31 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans, gastric and gastro-oesophageal junction (GEJ) adenocarcinomas are a major cause of cancer morbidity and mortality worldwide [6]. Although complete surgical resection is the mainstay of treatment for non-metastatic diseases, many patients are not diagnosed until their disease is either locally advanced or metastatic and therefore unresectable [6].…”

Section: Introductionmentioning

confidence: 99%

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

et al. 2014

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified as a predictor of resistance to anti-EGFR drugs. In human oncology, the importance of the EGFR/HER-2/KRAS signalling pathway in gastric cancer is well established, and HER-2 testing is required before initiating therapy. Conversely, this pathway has never been investigated in canine gastric tumours. A total of 19 canine gastric epithelial neoplasms (5 adenomas and 14 carcinomas) were retrospectively evaluated for EGFR/HER-2 immunohistochemical expression and KRAS mutational status. Five (35.7%) carcinomas were classified as intestinal-type and 9 (64.3%) as diffuse-type. EGFR was overexpressed (≥1+) in 8 (42.1%) cases and HER-2 (3+) in 11 (57.9%) cases, regardless of tumour location or biological behaviour. The percentage of EGFR-positive tumours was significantly higher in the intestinal-type (80%) than in the diffuse-type (11.1%, p = 0.023). KRAS gene was wild type in 18 cases, whereas one mucinous carcinoma harboured a point mutation at codon 12 (G12R). EGFR and HER-2 may be promising prognostic and therapeutic targets in canine gastric epithelial neoplasms. The potential presence of KRAS mutation should be taken into account as a possible mechanism of drug resistance. Further studies are necessary to evaluate the role of dog as a model for human gastric cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Most importantly, gastric carcinomas were found to have a different pattern of membrane staining-apical/incomplete, as opposed to the circumferential staining in breast cancer-and significant intratumoral heterogeneity of HER2 positivity. 78,79 As a result, distinct HER2 IHC scoring criteria and testing algorithms have been developed in gastric cancer to help the accurate determination of HER2 status and prediction of therapeutic response. Similarly, endometrial cancer-specific HER2 IHC testing and scoring guidelines need to be developed in the future to reflect the unique biology and pathogenetic features of these tumors.…”

Section: Her2 Overexpression By Ihcmentioning

confidence: 99%

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges

Buza

Roque

Santin

2014

Archives of Pathology &Amp; Laboratory Medicine

125

104

View full text Add to dashboard Cite

Context.-In the era of targeted cancer therapy, there is growing interest in developing novel therapeutic strategies against endometrial carcinoma, especially its most biologically aggressive variant, serous adenocarcinoma. Several publications have demonstrated that a significant proportion of uterine serous carcinomas show HER2 overexpression and/or amplification, suggesting that HER2 may be a promising therapeutic target. Case reports have already shown clinical response to trastuzumab, a humanized monoclonal immunoglobulin (Ig) G1 antibody against HER2, and patients are currently being enrolled in a multi-institutional prospective randomized trial to evaluate the therapeutic efficacy of trastuzumab.Objective.-To review current data on HER2 testing and targeted therapy against HER2/neu in endometrial carcinoma. Data Sources.-Review of the literature and personal experience of the authors.Conclusions.-Parallel to the clinical studies, there is a need to develop standardized criteria for HER2 testing in endometrial carcinoma that reflect the unique biological and pathogenetic features of these tumors and correlate with clinical response to therapy. This article presents a comprehensive review of the current state of HER2-based therapy and HER2 testing in endometrial carcinoma.

show abstract

“…Numerous studies were done from basic mechanism of HER family for cell proliferation and oncogenesis, HER2 overexpression or amplification in various solid tumors to clinical treatment of breast cancer, gastroesophageal cancer by trastuzumab in many recent reviews [1][2][3][4][5][6][7][8].…”

Section: Introduction Egfr and Her2 Family With Signal Pathway And Camentioning

confidence: 99%

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

Zhou¹,

Hick²

2013

Oncogene and Cancer - From Bench to Clinic

View full text Add to dashboard Cite

HER2 Testing in Gastric and Gastroesophageal Junction Cancers

Cited by 31 publications

References 9 publications

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

Contact Info

Product

Resources

About